International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203

The Economics of Pharmaceutical Pricing

Mr. Krushna Khadke*[1], Mr. Atharva Tilak[2], Mr. Wali Quereshi[3], Mrs. Priyanka Todkari[4], Mrs. Shraddha Dingare[5], Mrs. Dhanashri Borawake[6], Dr. Meera Deshmukh[7]

Lokmanya Tilak Institute of Pharmaceutical Sciences, Pune 411037 India.

Received: 2025-04-29 Revised: 2025-05-15 Accepted: 2025-05-25

ABSTRACT

Pharmaceutical pricing is a complex issue that requires balancing affordability, accessibility, and innovation in global healthcare. It directly impacts patients, healthcare providers, policymakers, and pharmaceutical companies. Key factors influencing pricing include research and development (R&D) costs, market exclusivity, competition, regulatory frameworks, and government policies. High drug prices can limit access to essential medications and strain healthcare systems, highlighting the need for transparent and fair pricing mechanisms. Numerous studies emphasize the importance of regulatory oversight to prevent excessive pricing and ensure equitable access. As chronic diseases become more prevalent and demand for affordable treatments rises, sustainable pricing strategies are essential. These must encourage innovation while ensuring medications remain within financial reach for all. Developing effective policies that balance economic and health priorities is critical to creating a fair, accessible, and innovative pharmaceutical landscape worldwide.

Keywords: Pharmaceutical pricing, drug affordability, healthcare access, innovation, research and development (R&D) costs

1. INTRODUCTION

Pharmaceutical pricing is a multifaceted issue that balances affordability, accessibility, and innovation within global healthcare systems. Drug pricing strategies impact patients, healthcare providers, policymakers, and pharmaceutical companies, making it a critical area of research and policy intervention. Various factors, including research and development (R&D) costs, market exclusivities, competition, regulatory frameworks, and government policies, contribute to the pricing mechanisms of pharmaceuticals [1] [2] . This introduction explores the significance of pharmaceutical pricing, key challenges, and the policy frameworks that influence drug costs worldwide. The Importance of Pharmaceutical Pricing: Pharmaceutical pricing plays a crucial role in healthcare access and expenditure. High drug costs can create financial burdens for patients and healthcare systems, limiting access to essential medications. Several studies have analyzed the economic implications of drug pricing, highlighting the need for transparency and regulation [3] [4]. The growing demand for cost-effective treatments, coupled with the increasing prevalence of chronic diseases, necessitates robust pricing strategies that ensure affordability without compromising innovation.

Pharmaceutical pricing remains a critical issue globally, balancing affordability, innovation, and economic sustainability. Various factors influence drug pricing, including research and development (R&D) costs, regulatory exclusivities, market dynamics, and government interventions. Government policies significantly impact pharmaceutical pricing structures. The National Pharmaceutical Pricing Policy (2012, India) and Reforms in the Pricing Framework (India) outline regulatory mechanisms to control drug prices while ensuring industry growth. Similarly, the U.S. Congressional Research Service reports highlight the role of patents and regulatory exclusivities in shaping drug costs. Schoonveld (2014) and Kolassa delve into strategic pricing approaches employed by pharmaceutical firms to navigate market and regulatory constraints.

Comparative analyses, such as those by the U.S. Department of Health and Human Services, demonstrate significant international disparities in drug pricing. Pontes et al. discuss variations in biological medicine prices due to different pricing policies. The BMJ (2020) and NBER (2023) papers address challenges in sustaining affordable drug pricing amid rising R&D costs. Meanwhile, Ballreich et al. (2017) propose frameworks to evaluate policy interventions aimed at managing branded prescription drug expenditures. Transparency in pharmaceutical pricing is another key theme, explored in-depth by Hinsch et al. (2014) and Iacocca & Mahar (2019), who examine cooperative partnerships and pricing mechanisms. Systematic reviews, such as those from BMJ Open (2021) and Springer (2024), emphasize the absence of a one-size-fits-all pricing model, advocating for country-specific policies that consider economic and healthcare system differences.

The role of India in reducing the cost of patented medicines has been widely acknowledged. Although the prices of patented medicines are cheaper in India, the retail markets are plagued by a number of flaws. Consequently, even with the presence of huge numbers of manufacturers, there are huge price variations between various brands of the same medicine. In India medications are bought chiefly by the patients themselves and not by the state or through sickness insurance. Due to the poor facilities of public health and insurance, availability to medicines has not been high in India. There is drug price control in one form or the other in India since 1963. India has, however, followed the selective strategy-while certain medications have been placed under control, competing medications were not allowed into control. This gave manufacturers a chance to halt or suspend production and sales of drugs under control and market the competing ones uncontrolled. India has reinstated product patent protection after 2005. MNCs have begun marketing new patented drugs at astronomical prices but these are not yet covered under price control. India has managed to limit product patents by excluding grant of patents under specific conditions. But potentially the more effective tool of compulsory licensing has gone unused in India.

2. Factors influencing pharmaceutical pricing

1.Research and Development (R&D) Costs

The cost of drug development is a major factor influencing pharmaceutical pricing. This process includes drug discovery, preclinical research, clinical trials, and regulatory approval, typically taking 10 to 15 years and involving significant financial risk. According to the Tufts Center for the Study of Drug Development, it costs approximately $2.6 billion to bring a new drug to market [1]. These substantial R&D expenses are often cited to justify high drug prices. DiMasi, Hansen, and Grabowski (2003) initially estimated the cost of developing a new drug at about $802 million (in 2000 dollars), covering preclinical and clinical stages, as well as the costs associated with failed drug candidates. This figure has been adjusted over time to account for inflation and other factors, as discussed by Chandra and Garthwaite (2017). The drug development timeline is lengthy and influenced by complex regulatory processes. Furthermore, since only a small percentage of drugs succeed in reaching the market, the costs of those that do must cover these risks, thus increasing the total cost of drug development [1].

2. Regulatory Environment and Government Policies

Governments influence drug pricing through regulations, price controls, and reimbursement policies. Some countries, such as Canada and the UK, negotiate drug prices through national agencies, while others, like the U.S., allow market-driven pricing (Babar, 2015). In India, the National Pharmaceutical Pricing Authority (NPPA) oversees the regulation of drug prices, particularly for essential medicines, which includes those on the National List of Essential Medicines. The NPPA's regulations are designed to keep medications affordable for the public, especially for low-income individuals. The promotion of generic drugs has also played a significant role in enhancing the affordability of medicines [1] [5]. Additionally, government policies often incorporate transparency initiatives, such as mandatory reporting of price hikes and price information systems. These measures ensure that any price increases are well-supported and prevent unjustified price surges [4]. In the United States, states like California have introduced laws that require pharmaceutical companies to notify the public ahead of price increases, thus fostering greater transparency and accountability in drug pricing [6]. The influence of patents and regulatory exclusivities is also a key factor in pricing strategies. Patents grant exclusive rights to drug manufacturers, enabling them to set higher prices due to the lack of competition. Once a patent expires, generic drugs typically enter the market, leading to reduced prices and increased competition [2].

3. Manufacturing and Distribution Costs

Manufacturing costs include raw materials, production, quality control, and logistics. Biologics, which require complex production and cold-chain storage, are significantly more expensive to manufacture compared to small-molecule drugs[7] . The costs associated with manufacturing and distributing pharmaceuticals are essential factors in determining the price of drugs. The production process involves a variety of stages, such as research and development, clinical testing, regulatory approvals, and large-scale manufacturing. DiMasi et al. (2003) highlight that the total cost of developing a drug—including research and trials—can amount to billions of dollars before a product reaches the market. These considerable expenses are typically reflected in the price's consumers pay. Beyond the manufacturing process, the distribution network plays a crucial role in drug pricing. This network includes intermediaries like wholesalers, distributors, and pharmacy benefit managers (PBMs), each contributing their markup to the final price[6]. These additional costs, alongside other operational expenses, significantly affect the overall price of medications. Manufacturers must also consider the expenses involved in maintaining a global supply chain to ensure widespread market access. This includes logistical costs, warehousing, and meeting regulatory standards, all of which further contribute to distribution costs [8].

4. Market Exclusivity and Patent Protection

Pharmaceutical patents provide companies with exclusive rights to market a drug for up to 20 years from the filing date. This exclusivity allows firms to set high prices without competition. Once patents expire, generic drugs enter the market, significantly reducing prices [2].

3. Techniques use to analyse pharmaceutical pricing

1. Cost-Based Pricing Analysis

This technique assesses pharmaceutical pricing based on the cost of production, research & development (R&D), regulatory compliance, and distribution. It helps determine whether drug prices reflect the actual cost of bringing a product to market. Studies have highlighted that high R&D costs significantly influence pricing strategies [1]. Setting medicine prices in the pharmaceutical industry using cost-based pricing analysis entails figuring out the entire cost of discovery, production, distribution, and marketing while maintaining a respectable profit margin. According to DiMasi, Hansen, and Grabowski (2003), this method usually involves full cost pricing, in which all costs, including marketing, manufacturing, R&D, and regulatory compliance, are taken into consideration before a markup is applied. Another approach, known as marginal cost pricing, is pertinent to public health programs and generic medications since it only considers variable costs [8]. One popular variation is cost-plus pricing, which sets selling prices by adding a certain percentage markup to production costs [4]. Furthermore, activity-based costing (ABC) ensures accurate pricing strategies by allocating costs to specific medications based on real resource utilisation [3].

2. External Reference Pricing (ERP)

Many countries use ERP to compare drug prices across different markets and set pricing benchmarks. This technique is commonly used in the European Union and emerging economies to ensure affordability and prevent excessive pricing disparities [2]. External Reference Pricing (ERP) is a commonly used approach in pharmaceutical pricing, where a country establishes the price of a drug by referencing its cost in other nations. This strategy is primarily adopted to regulate drug expenses, improve affordability, and provide a benchmark for price negotiations [3]. National regulatory bodies often rely on ERP to set upper price limits, particularly for branded prescription medications. The methodology for ERP differs across countries. Some adopt an average pricing model based on selected reference nations, while others determine prices based on the lowest or median value within the group [4]. Countries such as those in the European Union, as well as Canada and several Asian nations, utilize ERP to control pharmaceutical costs, which significantly affects both market entry and affordability [9]. The choice of reference countries is a crucial factor, as wealthier economies typically have higher drug prices, whereas lower-income regions experience cost adjustments to reflect affordability [1].

3. Value-Based Pricing (VBP) Analysis

This technique considers the therapeutic benefits of a drug relative to its price. It includes Quality-Adjusted Life Years (QALYs) and cost-effectiveness analysis to justify premium pricing for innovative drugs [10]. Value-Based Pricing (VBP) is a method used in pharmaceutical pricing that sets drug prices according to their clinical effectiveness and economic impact on patients and healthcare systems. Unlike cost-based or external reference pricing, VBP considers factors such as treatment effectiveness, improvements in patient quality of life, and cost reductions from fewer hospitalizations or alternative treatments [3] .This approach ensures that drug pricing aligns with patient outcomes, helping to maintain affordability while encouraging innovation [10]. Many VBP frameworks incorporate health technology assessments (HTAs) to compare a drug's cost-effectiveness with existing treatment options. Countries like Germany, the United Kingdom, and Sweden use HTA-based pricing strategies to determine reimbursement rates and negotiate fair prices with pharmaceutical companies (Babar, 2021). A key element in these assessments is the willingness-to-pay (WTP) threshold, which is often measured in terms of cost per quality-adjusted life year (QALY) [1].

4. Price Elasticity and Demand Sensitivity Analysis

This approach examines how changes in drug prices affect consumer demand. It is useful for understanding market access and the affordability of medications, particularly in developing economies [9]. Price elasticity and demand sensitivity analysis are crucial in pharmaceutical pricing, helping to determine how price variations influence consumer demand. The price elasticity of demand (PED) assesses how responsive drug consumption is to price shifts. When demand is highly elastic, even minor price changes significantly affect usage, whereas inelastic demand means that price fluctuations have little impact on consumption [3]. Many essential and life-saving drugs tend to have inelastic demand, requiring a balance between ensuring affordability and maintaining profitability [1]. Demand sensitivity analysis considers 000factors like patient income, insurance coverage, and the availability of alternative treatments to assess how pricing adjustments influence drug accessibility and market reach [4]. Countries with strict pricing regulations, such as Germany and the United Kingdom, rely on demand sensitivity insights to develop reimbursement strategies and negotiate reasonable drug prices [6]. Additionally, research indicates that excessive drug costs can reduce adherence

among uninsured or underinsured individuals, which may negatively impact health outcomes and increase overall healthcare expenses [2].

4. Regulatory and Policy Frameworks

4.1 The Drugs Prices Control Order

The National Pharmaceutical Pricing Authority is a government body in Indian jurisdiction that regulates the pricing of controlled bulk drugs and formulations according to the Drugs (Prices Control) Order. The National Pharmaceutical Pricing Authority is responsible for maintaining the availability of medicines and their affordable pricing as mandated by the Drugs (Prices Control) Order. When manufacturers exceed the maximum allowed price for restricted drugs the NPPA collects the financial difference from these companies.

The National Pharmaceutical Pricing Authority operates through the following functions:

- The organization implements the Drugs (Prices Control) Order rules through its authorized jurisdiction. The Authority handles all legal disputes that arise from its decisions.

- The Authority conducts monitoring operations to identify when medicines become scarce and develops strategies to remedy the situation.

- The organization collects data through a system which combines production statistics with export-import information and market data from specific companies along with corporate profitability figures about bulk drugs and formulations.

- The organization performs pricing analysis for pharmaceutical products while supporting these research studies.

- The Authority needs to follow established rules and official procedures when selecting officers and other staff members.

- The Central Government receives advice about potential drug policy changes from the Authority.

- The Authority provides help to the Central Government regarding parliamentary matters related to drug pricing [5].

5 Price Monitoring and Resource Units (PMRUs)

1.1The National Pharmaceutical Pricing Authority (NPPA)

It has been entrusted with the task of:

- Part I of the Drug (Prices Control) Order requires manufacturers to update the prices of scheduled formulations according to the government's periodic revisions.

- The responsibility of enforcing the prices that are officially notified falls on the government.

- The organization performs multiple functions which include supplying necessary information to the government regarding policy development and other matters related to medicine accessibility and affordability for all people.

1.2 The National Pharmaceutical Pricing Policy of 2012 empowers the National Pharmaceutical Pricing Authority (NPPA) to serve as the primary body responsible for enforcing drug pricing regulations. This ensures that the NPPA has the necessary resources and authority to effectively implement the policy and oversee compliance.

1.3 In line with this, the Drug (Prices Control) Order of 2013 (DPCO 2013) sets up a framework to regulate and monitor the production and distribution of essential medicines—referred to as scheduled formulations—along with their active pharmaceutical ingredients (APIs). It also keeps track of the pharmaceutical companies involved in manufacturing these medicines, helping to maintain transparency and control over drug prices in the interest of public health.

1.4 In the past, the National Pharmaceutical Pricing Authority (NPPA) refrained from conducting research to gather market-based data. The National Pharmaceutical Pricing Policy (NPPP) of 2012 along with the Drug (Prices Control) Order (DPCO), 2013 made market-based data collection essential for the NPPA's daily operations. The successful completion of data-based operations by NPPA

relies on the full support from State and Union Territory governments which establish Price Monitoring and Resource Units (PMRUs).

1.5 The Government established a new program through the Central Sector Scheme on Consumer Awareness, Publicity, and Price Monitoring to promote this purpose. The new initiative requires the establishment of PMRUs in all States and Union Territories. The units exist to support State Drug Controllers along with NPPA by delivering vital market information. Every PMRU functions as an essential NPPA partner by operating under the immediate control of its corresponding State Drug Controller. The PMRUs maintain a vital presence at community levels to supervise medicine price monitoring operations which enable the timely distribution of DPCO benefits to consumers[5].

5.2 Objective of PMRUs

- The primary aim of establishing PMRUs is to offer technical support to State Drug Controllers and the NPPA (National Pharmaceutical Pricing Authority) in strengthening the monitoring and enforcement of drug pricing policies.

- These units are designed to serve as essential tools in ensuring that medicines remain accessible and affordable to the public, while maintaining transparency and compliance with existing regulations like the Drug (Prices Control) Order (DPCO), as updated over time.

- The key responsibilities of PMRUs include: Price Monitoring and Compliance: PMRUs are tasked with tracking medicine prices to ensure they adhere to government-notified rates, identifying any violations of pricing rules, and confirming that essential medicines are available to consumers.

- Watching Price Trends: These units will monitor both scheduled and non-scheduled drug prices based on industry-submitted data. They will check for any unjustified price hikes—especially for non-scheduled drugs, which are not supposed to rise by more than 10% annually. They will also ensure that scheduled drugs are updated in line with changes in the Wholesale Price Index (WPI).

- Data Collection and Analysis: PMRUs will regularly gather and analyze market-based pricing data to support informed decision-making. Medicine Sampling: When needed, PMRUs may collect medicine samples from retail markets to ensure quality and compliance.

- Public Awareness: A critical role of the PMRUs is to conduct workshops, seminars, and training sessions at both the state and district levels. These activities will educate consumers about NPPA's role, the importance of drug pricing regulations, and how to access affordable medications. The training will be led by experts from State Drug Authorities and NPPA when required.

- Additional Tasks: PMRUs may also take on other assignments given by NPPA, as needed from time to time. To carry out these functions effectively, PMRUs will maintain regular communication with various stakeholders, such as state government departments, drug regulators, and consumer advocacy groups. While they will be deeply involved in gathering market insights and supporting enforcement, PMRUs will not engage directly with pharmaceutical companies. Their role is strictly technical and regulatory, supporting the larger goal of ensuring fair and affordable access to medicines across India[5].

5.3 Activities to be undertaken by PMRUs:

Price Monitoring and Resource Units (PMRUs) play a vital role in supporting the NPPA by gathering real-time, ground-level information on medicine pricing and availability. These units act as important partners in making sure that the benefits of the Drug Price Control Order (DPCO), as updated from time to time, actually reach people at the grassroots.

- Gathering Market Data: PMRUs actively collect, compile, and analyze market-based data related to both scheduled (price-regulated) and non-scheduled (non-regulated) medicines.

- Tracking Price Movements: By closely monitoring changes in the prices of medicines—both those under price control and others—PMRUs can spot unusual spikes and ensure price stability for consumers.

- Sampling Medicines: When required, PMRUs may purchase medicine samples directly from retail outlets. These samples are used to check product quality and verify compliance with price regulations.

- Public Awareness and Communication: PMRUs help keep the public informed by publishing newsletters, advertisements, and other materials that explain drug pricing policies and consumer rights.

• Educational Outreach: To further their awareness efforts, PMRUs organize training programs, seminars, and workshops at the state and district levels. These sessions focus on educating consumers about their rights, how drug pricing works, and what precautions to take when purchasing medicines.

Through these activities, PMRUs ensure that the objectives of drug price regulation policies are not just written in documents but are actively implemented and felt by people across all levels of society.[5]

5.4 Categories of States/ UTs for setting up the PMRU:

To ensure fair distribution of grants and resources under the Scheme, States and Union Territories have been grouped into three categories based on their population size. This classification helps determine the level of staffing, infrastructure, and financial support each region will receive:

• Category I: Includes States and UTs where the population exceeds 3% of the country's total population. These regions require more resources due to their larger populations.

• Category II: Covers those with a population between 1% and 3% of the national total. These areas receive moderate levels of support based on their needs.

• Category III: Comprises States and UTs with less than 1% of the country's total population. These regions, while smaller, are still provided with tailored support to ensure they can effectively implement the scheme[5].

6. CONCLUSION:

Pharmaceutical pricing is a multidimensional issue shaped by scientific innovation, market dynamics, policy interventions, and ethical considerations. The cost of drug development, including lengthy research phases and regulatory approvals, significantly impacts pricing structures. However, this justification alone does not fully explain the high and often inconsistent prices observed globally. Divergent national policies, varying regulatory environments, and differing levels of market competition contribute to disparities in drug prices across regions. Emerging markets and developing countries face additional challenges due to limited negotiation power, fragmented healthcare systems, and issues with transparency.

Efforts to introduce greater price transparency, value-based pricing, and indication-specific models aim to align costs with clinical benefits and societal value. Nevertheless, these initiatives are constrained by complexities in data access, stakeholder alignment, and implementation capacity. Price regulation strategies—such as reference pricing, cost sharing, and negotiated procurement—have had mixed outcomes, often influenced by the political and economic context in which they are applied.

The debate over balancing innovation incentives with affordability continues to evolve. While patent protections and regulatory exclusivities encourage investment in research and development, they can also delay generic entry and maintain high prices for extended periods. Cooperative partnerships, pricing reforms, and international benchmarking are increasingly being explored as ways to ensure that life-saving medicines are both innovative and accessible. Ultimately, no single pricing model fits all contexts. A hybrid, adaptable approach, underpinned by transparency, cross-sector collaboration, and evidence-based policymaking, is essential for creating sustainable pharmaceutical pricing systems that serve both public health and industry viability.

7. REFERENCES

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. *J Health Econ*. 2003;22:151–85.
2. Schoonveld E. *The price of global health: drug pricing strategies to balance patient access and the funding of innovation*. London: Routledge; 2016.
3. Ballreich JA, Chandra AG, Smith M, Thompson K, Grabowski AG. Branded prescription drug spending: a framework to evaluate policy options. *J Pharm Policy Pract*. 2017;10:31.
4. Hinsch MA, Siegel SS. Enhancing medicine price transparency through price information mechanisms. *Glob Health*. 2014;10:1–11.
5. Ministry of Chemicals and Fertilizers, Government of India. National Pharmaceutical Pricing Authority [Internet]. New Delhi: Government of India; 2025 [cited 2025 Jun 2]. Available from: https://pharma-dept.gov.in/national-pharmaceutical-pricing-authority
6. Babar ZUD. *Formulating and implementing pharmaceutical pricing policies*. Qatar; 2023.

7. Pontes MA, Afonso RA, Cordero LS. Comparative price analysis of biological medicines: disparities generated by different pricing policies. *Front Pharmacol*. 2024;14:1256542.
8. Kolassa E. *The strategic pricing of pharmaceuticals*. Essex: Pondhouse Press; 2009.
9. Babar ZUD. *Pharmaceutical prices in the 21st century*. Qatar: Springer; 2015.
10. Chandra AG. The economics of indication-based drug pricing. *N Engl J Med*. 2017;377:103–6.
11. Bhambere DD, Soni AD, Patel KR. *Pharma marketing management* [Internet]. Bhumi Publishing; 2022 [cited 2025 Jun 2]. Available from: https://www.bhumipublishing.com/wp-content/uploads/2022/02/Pharma-Marketing-Management.pdf
12. Iacocca KM, Singh MS. Cooperative partnerships and pricing in the pharmaceutical supply chain. *Int J Prod Res*. 2019;57:1724–40.
13. Morgan SG, Smith BH. Pricing of pharmaceuticals is becoming a major challenge for health systems. *BMJ*. 2020;368.
14. Daalen JM, Manders AE, van der Burgh VH. Determinants of drug prices: a systematic review of comparison studies. *BMJ Open*. 2021;11:e046917.
15. Borges Dos Santos MA, dos Santos RM, de Souza CG. Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science. *J Pharm Policy Pract*. 2019.
16. Frech MJ, Shaw CW. *Pharmaceutical pricing and R&D as a global public good*. Cambridge (MA): National Bureau of Economic Research; 2023.
17. Manders EC, van den Berg SJ. Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. *Eur J Health Econ*. 2024;1–14.
18. U.S. Bureau of Labor Statistics. *The pharmaceutical industry: an overview of CPI, PPI, and IPP methodology*. Washington (DC): U.S. Bureau of Labor Statistics.
19. Hahn JK. *Selected issues in pharmaceutical drug pricing*. Washington (DC): U.S. Congressional Research Service; 2022.
20. Hickey KJ. *The role of patents and regulatory exclusivities in drug pricing*. Washington (DC): U.S. Congressional Research Service; 2024.
21. Mulcahy AW, Chandra AG, Domingues S, Nunnery D. *International prescription drug price comparisons*. Santa Monica (CA): RAND Corporation; 2021.
22. U.S. Government. *National Centre for Biotechnology Information*. Bethesda (MD): U.S. National Institutes of Health.
23. Vogler S, Zimmermann N. International price comparisons of pharmaceuticals: a review of the literature. *Health Policy*. 2019;123(9):855–64.
24. Ferriero AM, Veneziano MA, Specchia ML. Pharmaceutical policies: the effects of reference pricing, cost sharing, and risk sharing on public expenditure. *Eur J Public Health*. 2013;23 Suppl 1:ckt123.136.
25. Abdel Rida N, Mohamed Ibrahim MI, Babar ZUD, Owusu Y. A systematic review of pharmaceutical pricing policies in developing countries. *J Pharm Health Serv Res*. 2017;8(4):213–26.
26. Verghese NR, Barrenetxea J, Bhargava Y, Agrawal S, Finkelstein EA. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. *J Mark Access Health Policy*. 2019;7(1):1601060.
27. Aryal G, Ciliberto F, Farmer LE, Khmelnitskaya E. Valuing pharmaceutical drug innovations. *arXiv* [Preprint]. 2022.
28. Ahmad N, Hatah E, Makmor-Bakry M. Association between medicine price declaration by pharmaceutical industries and retail prices in Malaysia's private healthcare sector. *J Pharm Policy Pract*. 2019;12:15.
29. Babar ZUD, Scahill S. Is there a role for pharmacoeconomics in developing countries? *Pharmacoeconomics*. 2010;28(12):1069–74.
30. Gustafsson LL, Wettermark B, Godman B, et al. The 'wise list' – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. *Basic Clin Pharmacol Toxicol*. 2011;108(4):224–33.
31. Newham M, Valente M. The cost of influence: how gifts to physicians shape prescriptions and drug costs. *arXiv* [Preprint]. 2022.
32. World Health Organization. WHO publishes pricing policy guideline to improve affordable access to medicines. *WHO News*. 2020.

How to cite this article:
Mr. Krushna Khadke et al. Ijppr.Human, 2025; Vol. 31 (6): 266-272.

Conflict of Interest Statement: All authors have nothing else to disclose.